Home > Healthcare > Biotechnology > Biotechnology R&D > Biopharmaceutical Fermentation Systems Market

Biopharmaceutical Fermentation Systems Market Share

Report ID: GMI9589
Published Date: May 2024
Report Format: PDF

Download Free Sample

Biopharmaceutical Fermentation Systems Market Share

The market is moderately fragmented. Established market players have been focusing towards launching new fermentation systems with advanced features such as advanced control units and single-use capabilities. Furthermore, established companies have substantial manufacturing expertise and experience, that they are leveraging to enhance their product features. Small companies are adopting lower pricing strategies and are focusing towards offering fermentation systems for the specific applications to remain competitive, which has contributed to the overall diversity in the market.

Biopharmaceutical Fermentation Systems Market Companies

Prominent players operating in the biopharmaceutical fermentation systems industry include:

Agilent Technologies, Inc.
Becton, Dickinson and Company
Bioengineering AG
Cellexus Limited
Danaher Corporation
Eppendorf AG
F. Hoffmann-La Roche Ltd.
GE HealthCare Technologies, Inc.
Getinge Group
Lonza Group AG
Merck KGaA
Nova Biomedicals
Sartorius Stedim Biotech
Thermo Fisher Scientific Inc.
ZETA

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The biopharmaceutical fermentation systems market size was valued at USD 11.5 billion in 2023 and is anticipated to grow at 6% CAGR from 2024 – 2032, owing to growing demand for biopharmaceuticals and hefty investments for developing new biopharmaceuticals.

The upstream products segment in the market held 62.2% share in 2023, driven by the increasing investments in biopharmaceutical research for the development of new and advanced therapies.

North America biopharmaceutical fermentation systems market accounted for 41.4% share in 2023 and is predicted to reach USD 7.7 billion by 2032, attributed to the presence of large number of biopharmaceutical companies offering advanced treatment options.

Agilent Technologies, Becton, Dickinson and Company, Bioengineering AG, Cellexus Limited, Danaher Corporation, Eppendorf AG, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies, Inc., Getinge Group, Lonza Group AG, Merck KGaA, Nova Biomedicals, Sartorius Stedim Biotech, Thermo Fisher Scientific Inc., and ZETA